Skip to content
Agentic OS
Menu

Intelligence / Healthtech / PMA Approvals / Ethicon, INC.

Approvalsdevice change approved (PMA)27 Aug 2026

Ethicon, INC.

27 Aug 2026: Device change approved (PMA) · ETHIZIA™ Hemostatic Patch. Recorded in the openFDA device PMA data.

View the source record

Decided
27 Aug 2026
Device
ETHIZIA™ Hemostatic Patch
Specialty
General, Plastic Surgery
Type
Supplement (Normal 180 Day Track No User Fee)
Reason
Location Change - Manufacturer/Sterilizer/Packager/Supplier
Reference
P240035 S004
Location
Raritan, NJ
What this signal means

A PMA approval is a high-risk device launch: reimbursement, distribution, clinical training and sales hires follow.

  1. Cardiovascular leads with 53 of 120, then Pathology (15).
  2. 35 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at Ethicon, INC.

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this approvals signal, for your approval.

Start free

Across AOS Research

Other records for Ethicon, INC. in our registers.

More in General, Plastic Surgery

PMA Approvals

See all

Source: openFDA device PMA data, data to 18 Nov 2026. Class III devices approved by FDA: original approvals and supplements that change the device (180-day, panel-track and special tracks). 30-day manufacturing notices are left out. AOS shows what the public record says; it does not verify or endorse the company.